MARKHAM, ON/24-7PressRelease/ — After
several years of scientific and biomedical laboratory experiments, Ensil
succeeds in developing a nanotechnology-based sensor to detect gp 21 and gp 27
HIV virus through urine.

“After several years of scientific and biomedical
laboratory experiments to develop nanotechnology-based sensors and detectors,
we are extremely proud to make this announcement,” said Farsad Kiani,
Presiden and CEO of Ensil Group of Companies.

Mr. Kiani continued, “When the Ensil Canada Ltd. HIV
diagnostic device is commercialized and put on the market, high-risk groups may
get tested at more convenient locations as a do-it-yourself, real-time,
cost-effective way to test and receive their own test results in strictest
confidence.”

Ensil Canada Ltd. Chief Scientist and the Lead Project CSO
added after the successful experiments with the antibody to HIV gp41, Ensil
will try to validate the same results with its proprietary detection technology
to detect gp120 so a wide range of HIV strain could be detected.

Ensil Canada Ltd., a member of Ensil group of companies (www.ensil.com) focuses on
enhancing mission critical technologies in the areas of aerospace, defence,
telecommunication and medical diagnostic equipment. Ensil’s R&D divisions’
mission is to develop new technologies or improve existing technologies through
in-house research activities. After nearly 30 years of scientific and
technological experience, Ensil has required resources to modify, re-design,
reverse engineer or repair circuit boards and assemblies used in medical, industrial
and military equipment.

For further information please contact us at: info@ensil.ca or visit us at www.ensil.ca.